EODData

MEMBERSHIP REGISTER LOG IN

FRA, NKB2: TG Therapeutics Inc

05 Nov 2025
LAST:

29.00

CHANGE:
 0.28		OPEN:
29.00		HIGH:
29.00		ASK:
0.00		VOLUME:
80
CHG(%):
0.96		PREV:
28.73		LOW:
29.00		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Nov 2529.0029.0029.0029.0080
04 Nov 2528.7328.7328.7328.7380
03 Nov 2530.6730.9030.6730.9080
31 Oct 2529.3431.5129.3431.513.1K
30 Oct 2529.1229.1229.1229.1245
29 Oct 2529.5029.5029.5029.5045
28 Oct 2528.6028.6028.6028.6045
27 Oct 2528.3328.3328.3328.3345
24 Oct 2528.5228.5228.5228.5245
23 Oct 2529.4429.4429.4429.4445

COMPANY PROFILE

Name:TG Therapeutics Inc
About:TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Sector:Healthcare
Industry:Biotechnology
Address:3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560
Website:https://www.tgtherapeutics.com
ISIN:US88322Q1085
LEI:529900X21UKABN9NJ529

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:11.97 
Forward P/E:-12.54 
PEG Ratio:0.04 
Price to Sales:8.57 
Price to Book:15.09 
Profit Margin:0.84 
Operating Margin:0.18 
Return on Assets:0.04 
Return on Equity:0.11 
Revenue:461.63M 
EBITDA:84.81M 
Shares:158.67M 
Market Cap:4.601B 

TECHNICAL INDICATORS

MA5:29.852.9%
MA10:29.361.2%
MA20:29.461.6%
MA50:28.422.0%
MA100:28.641.3%
MA200:30.575.4%
STO9:21.10
STO14:21.10
RSI14:46.30
WPR14:-78.90
MTM14:-0.40
ROC14:-0.01 
ATR:0.70 
Week High:31.518.6%
Week Low:28.731.0%
Month High:31.518.6%
Month Low:28.335.4%
Year High:39.8937.5%
Year Low:22.3529.8%